Compare Cadila Healthcare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 14.4 27.0 53.4% View Chart
P/BV x 2.8 2.3 120.6% View Chart
Dividend Yield % 1.5 0.7 212.5%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
SUN PHARMA
Mar-19
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs558679 82.2%   
Low Rs362375 96.3%   
Sales per share (Unadj.) Rs116.3121.1 96.0%  
Earnings per share (Unadj.) Rs17.913.4 133.6%  
Cash flow per share (Unadj.) Rs23.120.7 111.8%  
Dividends per share (Unadj.) Rs3.502.75 127.3%  
Dividend yield (eoy) %0.80.5 145.9%  
Book value per share (Unadj.) Rs85.4172.6 49.5%  
Shares outstanding (eoy) m1,023.742,399.26 42.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.4 90.9%   
Avg P/E ratio x25.739.4 65.3%  
P/CF ratio (eoy) x19.925.5 78.0%  
Price / Book Value ratio x5.43.1 176.2%  
Dividend payout %19.620.6 95.3%   
Avg Mkt Cap Rs m470,6641,264,650 37.2%   
No. of employees `00011.817.5 67.5%   
Total wages/salary Rs m18,54559,671 31.1%   
Avg. sales/employee Rs Th10,072.716,608.1 60.6%   
Avg. wages/employee Rs Th1,569.13,409.6 46.0%   
Avg. net profit/employee Rs Th1,547.71,833.8 84.4%   
INCOME DATA
Net Sales Rs m119,049290,659 41.0%  
Other income Rs m1,13210,255 11.0%   
Total revenues Rs m120,181300,914 39.9%   
Gross profit Rs m28,47563,076 45.1%  
Depreciation Rs m5,38817,533 30.7%   
Interest Rs m9115,553 16.4%   
Profit before tax Rs m23,30850,246 46.4%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m5,6446,009 93.9%   
Profit after tax Rs m18,29232,093 57.0%  
Gross profit margin %23.921.7 110.2%  
Effective tax rate %24.212.0 202.5%   
Net profit margin %15.411.0 139.2%  
BALANCE SHEET DATA
Current assets Rs m82,005310,692 26.4%   
Current liabilities Rs m60,720173,396 35.0%   
Net working cap to sales %17.947.2 37.9%  
Current ratio x1.41.8 75.4%  
Inventory Days Days7399 73.8%  
Debtors Days Days98112 88.1%  
Net fixed assets Rs m83,703232,477 36.0%   
Share capital Rs m1,0242,399 42.7%   
"Free" reserves Rs m86,421411,691 21.0%   
Net worth Rs m87,445414,091 21.1%   
Long term debt Rs m25,55115,226 167.8%   
Total assets Rs m180,653646,938 27.9%  
Interest coverage x26.610.0 264.5%   
Debt to equity ratio x0.30 794.7%  
Sales to assets ratio x0.70.4 146.7%   
Return on assets %10.65.8 182.7%  
Return on equity %20.97.8 269.9%  
Return on capital %22.010.2 216.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68366,025 64.6%   
Fx outflow Rs m11,24238,610 29.1%   
Net fx Rs m31,44127,415 114.7%   
CASH FLOW
From Operations Rs m9,19321,965 41.9%  
From Investments Rs m-9,737-6,813 142.9%  
From Financial Activity Rs m515-27,305 -1.9%  
Net Cashflow Rs m-29-8,442 0.3%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  ABBOTT INDIA  PANACEA BIOTECH  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 18, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS